10-Q/A: Bio Essence Corp. Files Amended 10-Q/A Report Following Internal Control Issues and Discontinued Operations

Bio Essence Corp. has filed an amended quarterly report to address internal control deficiencies and reflect the sale of two subsidiaries, impacting financial results for the period ending March 31, 2024.

Summary

• Bio Essence Corp. filed an amendment to its Form 10-Q for the quarter ended March 31, 2024, primarily to update disclosures regarding internal controls.
• The company has restated its financial statements due to errors in accounting for certain historical transactions.
• Bio Essence sold its subsidiaries, Bio Essence Pharmaceutical Inc. (BEP) on December 31, 2023, for $300,000 and Bio Essence Herbal Essentials, Inc. (BEH) on April 1, 2024, for $400,000, resulting in gains on disposal.
• The company reported a net income of $133,939 for the quarter, which includes a gain from discontinued operations of $256,925.
• The company's continuing operations reported a net loss of $122,986 for the quarter.
• The company's current liabilities exceed current assets, resulting in a working capital deficit of $2,021,158 and a current ratio of 0.31:1.
• The company has an accumulated deficit of $9,006,535 from continuing operations as of March 31, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document reveals significant financial and operational challenges, including a net loss from continuing operations, a substantial working capital deficit, ineffective internal controls, and a going concern warning. While there was a net income due to the sale of subsidiaries, the underlying business is struggling.

Positives

• The company generated a net income of $133,939 for the quarter, primarily due to gains from the sale of subsidiaries.
• The sale of BEP and BEH generated a total of $700,000 in cash.
• The company is actively seeking ways to improve its financial position, including strengthening its sales force and exploring additional financing options.

Negatives

• The company's continuing operations reported a net loss of $122,986 for the quarter.
• The company has a significant working capital deficit of $2,021,158.
• The company's internal controls over financial reporting were deemed ineffective.
• The company has a substantial accumulated deficit of $9,006,535 from continuing operations.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company has no revenue from continuing operations for the three months ended March 31, 2024 and 2023.

Risks

• The company's ability to continue as a going concern is uncertain due to its accumulated deficit and ongoing losses.
• The company's internal control weaknesses could lead to further financial misstatements.
• The company's reliance on loans from a major shareholder poses a risk if that funding source becomes unavailable.
• The company may not be able to secure additional funding on acceptable terms or at all.
• The company's lack of revenue from continuing operations is a significant concern.

Future Outlook

The company plans to increase income by strengthening its sales force, providing attractive sales incentive programs, and increasing marketing and promotion activities. Management also intends to raise additional funds through private or public offerings or by obtaining loans. However, there is no assurance that the company will be able to obtain additional funding.

Management Comments

• Management believes in the viability of its strategy to generate sufficient revenue.
• Management intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others.
• Management concluded that, as of March 31, 2024, the company's internal control over financial reporting were not effective at the reasonable assurance level.

Industry Context

The health supplement industry is competitive, and Bio Essence's financial challenges highlight the difficulties faced by smaller companies in this sector. The company's shift to focus on integrative healthcare practitioners is a common strategy to differentiate in a crowded market. The sale of subsidiaries indicates a strategic shift away from manufacturing and distribution.

Comparison to Industry Standards

• The company's negative working capital and low current ratio are significantly below industry benchmarks for a going concern.
• Many companies in the health supplement industry have positive working capital and current ratios above 1:1.
• The company's lack of revenue from continuing operations is unusual for a company that has been in business for over 20 years.
• The company's reliance on loans from a major shareholder is not a typical funding model for a public company.
• The company's internal control weaknesses are a significant concern and are not typical for a public company.

Related Party Transactions

• The company has loans from a major shareholder (also a senior officer) totaling $1,370,746 as of March 31, 2024.
• The company has a loan from another major shareholder for $608,631 for settling litigation.
• These loans are unsecured, non-interest bearing, and have no fixed terms of repayment.
• A debt-to-equity conversion occurred on June 2, 2023, where a major shareholder received 5,000,000 shares in exchange for $2,500,000 of debt.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be concerned about job security due to the company's financial challenges.
• Customers may be concerned about the company's ability to continue operations and provide products.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will work to develop and implement effective internal controls.
• The company will continue to explore options to secure additional financing.
• The company will focus on strengthening its sales force and increasing marketing efforts.

Key Dates

Keywords

internal controls, discontinued operations, financial restatement, going concern, net loss, working capital, subsidiary sale, health supplements, debt financing